Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5998698

Title:Transgenic fish capable of expressing exogenous lytic peptides
Inventors:Cooper, Richard K.; Baton Rouge, LA, USA
Enright, Frederick M.; Baton Rouge, LA, USA
Summary:Described herein is a transgenic fish capable of expressing native exogenous lytic peptides which confer resistance to diseases caused by intracellular bacteria, protozoa and viruses. The invention relates to methods of increasing the resistance of a mammalian host to diseases according to a model based upon a transgenic catfish whose genome comprises a gene encoding cecropin B operably linked to the native cecropin B promoter, such that the expression of the cecropin B gene imparts resistance to pathogenic bacteria. Claims of the invention include genes coding for a cecropin or other native or synthetic lytic peptide which can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other mammalian cells. Further disclosed are the properties of such transformed cells in producing and secreting a broad-spectrum chemotherapeutic agent that has a systemic effect on certain pathogens, particularly on pathogens that might otherwise evade or overcome host defenses. Therapeutic applications to a variety of human diseases caused by bacteria, protozoa and viruses are included.
Abstract:Novel means have been discovered for increasing the resistance of an animal host (including humans) to diseases caused by intracellular bacteria, protozoa, and viruses. The infection treated may, for example, be equine infectious anemia, or infection by the human immunodeficiency virus. Novel means have also been found for treating tumors Augmentation of the host's defenses against infectious diseases or tumors is achieved by arming the host's cells with an exogenous gene encoding a natural or synthetic lytic peptide. For example, the transfection of hematopoietic stem cells and embryonic cells will produce animals with enhanced disease resistance; and transfection of TIL (tumor infiltrating lymphocytes) cells or other cells can be used in the treatment of tumors. Genes coding for a cecropin or other native or synthetic lytic peptide can be transferred and stably expressed in mammalian, bony fish, other vertebrate, and other animal cells. The transformed cells have the ability to produce and secrete a broad spectrum chemotherapeutic agent that has a systemic effect on certain pathogens, particularly pathogens that might otherwise evade or overcome host defenses.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5998698
Application Number:US1995000491609
Date Filed:07/06/1995
Date Published:07/12/1999
Assignee:Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Baton Rouge, LA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  8/12/2020